LS9

LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets

LS9 Wins Sustainable Biofuels Technology Award Presented by World Biofuels Markets

February 16, 2012

 SOUTH SAN FRANCISCO, Calif., Mar 16, 2012 (GlobeNewswire via COMTEX) -- LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced the Company was chosen by an independent panel of judges as the winner of the Sustainable Biofuels Technology Award presented at the World Biofuels Markets Congress and Exhibition 2012 taking place March 13-15, 2012 at the Beurs-World Trade Center, in the Rotterdam, Netherlands ( www.worldbiofuelsmarkets.com ).<

Black Duck Software, Inc.

Tom Bogan Joins Black Duck Software as Chairman of the Board

Tom Bogan Joins Black Duck Software as Chairman of the Board

March 15, 2012

BURLINGTON, Mass., March 15, 2012 -- Black Duck Software, the leader in open source software knowledge,

Celexion LLC

CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals

CELEXION Awarded Patent on Biosynthesis of Renewable Chemicals

March 14, 2012

CAMBRIDGE, Mass., March 14, 2012

Oasys Water, Inc.

Oasys Water Taps Select Energy Services as First Partner in The Oil and Gas Industry

Oasys Water Taps Select Energy Services as First Partner in The Oil and Gas Industry

March 14, 2012

Boston, MA, (March 14, 2012) – Oasys Water, a provider of forward osmosis technology that lowers the cost to reuse water, today announced that Select Energy Services, LLC (SES), a leading provider of engineered water solutions to the oil and gas industry, will be the exclusive operator of Oasys’ technology in the Permian Basin, for a 24 month period.

Avedro, Inc.

Avedro Announces FDA Submission for Corneal Cross-linking

Avedro Announces FDA Submission for Corneal Cross-linking

March 8, 2012

WALTHAM, Mass., Mar 08, 2012 -- Avedro, Inc. announced today that the Company submitted a New Drug Application (NDA) to the United States Food and Drug Administration (FDA) for its VibeX(TM) (riboflavin ophthalmic solution) /KXL(TM) System for the treatment of keratoconus and corneal ectasia following refractive surgery.

 

LS9

LS9 Hires Gary Juncosa as Executive Vice President of Chemicals

LS9 Hires Gary Juncosa as Executive Vice President of Chemicals

March 7, 2012

SOUTH SAN FRANCISCO, Calif., Mar 7, 2012 -- LS9, Inc., a technology leader in the development of renewable and sustainable products, today announced the hiring of Gary Juncosa as Executive Vice President of Chemicals. Mr. Juncosa's responsibilities will include overall responsibility for the development and commercialization of LS9's chemical business.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-499 for the Treatment of Diabetic Nephropathy

Concert Pharmaceuticals Initiates Phase 2 Clinical Trial Evaluating CTP-499 for the Treatment of Diabetic Nephropathy

March 5, 2012

LEXINGTON, Mass.--(BUSINESS WIRE)--Mar 5, 2012 - Concert Pharmaceuticals, Inc. today announced the initiation of dosing in a Phase 2 clinical trial evaluating CTP-499, an investigational drug for the treatment of diabetic nephropathy, the leading cause of chronic kidney disease (CKD) in the US.

Affinnova, Inc.

Innovation Software Produces Products Twice as Successful in the Marketplace, According to Affinnova Study

Innovation Software Produces Products Twice as Successful in the Marketplace, According to Affinnova Study

March 1, 2012

WALTHAM, Mass.--()--A recent study by Affinnova, Inc., the global leader in innovation software and services, quantified the boost that products identified through concept optimization technology can expect in market.

Concert Pharmaceuticals, Inc.

Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System

Avanir Pharmaceuticals and Concert Pharmaceuticals Announce License Agreement to Develop and Commercialize Deuterium-modified Dextromethorphan for Disorders of the Nervous System

February 29, 2012

ALISO VIEJO, Calif. and LEXINGTON, Mass., Feb. 29, 2012 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (Nasdaq: AVNR) and Concert Pharmaceuticals, Inc.

Selventa

Selventa Announces a Research Agreement to Understand Mechanisms of Disease

Selventa Announces a Research Agreement to Understand Mechanisms of Disease

February 27, 2012

CAMBRIDGE, Mass., Feb 27, 2012 (BUSINESS WIRE) -- Selventa(TM), a personalized healthcare company focused on stratification of patients and development of predictive biomarker panels based on disease-driving mechanisms, today announced a research agreement in the area of immunological disease with Janssen Research & Development, LLC. The focus of this multi-year research agreement includes development of disease models using diverse biologic data to elaborate disease-relevant mechanisms and identify potential new drug discovery opportunities.